Direct oral anticoagulants (DOACs) have changed the management of venous thromboembolism (VTE). In recent years their use has extended to the realm of cancer-associated VTE (CAT), but experts warn that a paucity of trial data in that setting should breed caution in the care of patients with haematological malignancies. “Given the escalated risk of VTE ...
Cancer-associated VTE: can evidence for DOACs be extrapolated to haematological cancers?
By Dave Levitan
1 Mar 2021